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ABSTRACT 
 
Objectives 
The study aims to describe the socio-demographic characteristics, clinical outcomes of 
the patients in the Gauteng public sector roll-out programme and establish the 
association between these. There are contradictory results from international studies on 
these associations, in the absence of SA results. 
 
Methods 
This is a retrospective cohort, exploratory, secondary data, record review study and a 
comparison between two sites. Routinely collected socio-demographic data and clinical 
data were used to establish the impact of socio-demographic factors on response to 
HAART. This was collected for patients who enrolled from April 2004 to August 2004. 
Chris Hani Baragwanaath (CHB) had 494 records, Helen Joseph (HJ) had159 records 
collected. Exposure variables (age, sex, marital status, education level, residential area, 
employment, baseline viral load and baseline cd4 count). Outcome variables were (CD4 
and Viral load at 3 months, 6 months and 12 months). 
 
Data Analysis 
T tests were used for comparing means; logistic regression was used to find the effect of 
ordered exposure variables and binary outcome. Chi square and fishers exact were 
used to find frequencies and association between the categorical variables.  Regression 
was used to find the association between the continuous exposure variables and the 
continuous outcome variables. In a multivariate model, to assess the effect of the 
exposure variables to the outcome variables Multivariate regression was used. 
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Statistical significance was assessed at the 5% significance level, giving 95% confidence 
interval. 
 
Results 
The majority of the patients (653) were female, African, unemployed and were literate. 
At CHB, at the end of the first year, three quarters were still on treatment however; just 
under a fifth (19%) had died. The majority responded well to treatment and had a mean 
baseline CD4 count of 58.9cells/mm3 (CHB) and 78.4cells/mm3 (HJ) and mean CD4 
count of 245 (CHB) and 268 (HJ) after 12 months.  increasing age, and being widowed, 
lowers the immunological response. Employment, education, sex and had no impact on 
response. 
 
Conclusion 
• There is positive virological and immunological response to HAART in Gauteng 
ARV roll-out programme despite the low socio economic status of the majority of 
the patients. 
• Provision of free antiretroviral drugs and access to the disability grant has 
assisted in mitigating the effects of HIV/ AIDS on the socio-economically 
disadvantaged. 
• The elderly and the widowed might need close monitoring as their response 
appears to be lower than the others. 
• The group with no schooling is not well represented in this sample; the question 
is whether the HIV/AIDS prevention messages and treatment is accessible for 
this group. This needs further research. 
Key words: socio demographic, ART, CHB, HJ South Africa, HIV 
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 CHAPTER 1 INTRODUCTION 
1.1 Background 
Sub-Saharan Africa bears a disproportionate burden of the HIV/AIDS epidemic, which in 
North America and Europe has since become a manageable health problem after the 
advent of triple antiretroviral therapy as pointed out by Flanigan and others.1 In 2006, more 
than 63% of all the people living with HIV were in Africa, Southern Africa being the epicenter 
of the global HIV epidemic.2 There has been a noticeable increase in access to antiretroviral 
therapy in developing countries. According to the WHO Director Southern Africa, the 
number of HIV-positive Africans accessing AIDS Drug treatment has grown from less than 
300 000 in 2003 to more than 1 million by June 2006. In Sub-Saharan Africa however only 
23 percent of those in need of antiretroviral are receiving them.3 Scale-up efforts have been 
strong in some countries in East and Southern Africa, South Africa being one of them.2
As per UNAIDS (2004) report, South Africa continues to have the highest number of people 
living with HIV in the world.4 It is estimated that by the middle of 2006 about 5.4 million 
people in the South African population were infected with HIV.5 It is one of the countries in 
Sub-Saharan Africa that embraced the WHO 3 by 5 initiative. A number of public health 
centers countrywide are already providing free antiretroviral drugs to the qualifying 
HIV/AIDS patients. This is anticipated to be one of the largest roll out programs in the 
world.6 By the end of August 2004, four sites in Johannesburg Metro had enrolled a total of 
2301 patients into the ARV roll-out programme.7 According to the Gauteng Department of 
Health (April 2005), within the first year of roll out, the Gauteng provincial government had 
successfully opened 23 service points and had about 12 208 patients on antiretroviral 
therapy. By the middle of 2006, it was estimated that 230 000 HIV-infected individuals were  
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 receiving antiretroviral therapy in South Africa.5 According to the Deputy President of South 
Africa by September, 213 282 people countrywide had benefited from the government roll-
out programme and another 11 000 were joining the program every month.8 
Prior to public sector roll-out programme, those who could afford ARV treatment sourced 
their treatment privately or through company initiatives or non-governmental organizations 
like Medecins Sans Frontieres (MSF) and clinical trials. Due to high costs some of the 
patients were not taking adequate doses and combinations. 
 The public sector roll-out program is open to any South African who is HIV positive, has a 
CD4 count of less than 200cells/mm3 and meets the criteria spelt out in the National ARV 
Plan,9 whether treatment naïve or not. In this context challenges brought about by being not 
naive, socio-demographic features and questionable adherence are anticipated to interfere 
with response to HAART. 
The not-naïve group will present with a multitude of challenges which will range from 
treatment failure due to non adherence or drug resistance due to inadequate combinations 
and doses. Response to HAART in this group is expected not to be the same as in the 
naïve group. Compared with ART-experienced patients, ART-naïve patients were less likely 
to experience treatment failure.10
In the South African roll-out programme, all ARV drugs and laboratory tests are available for 
free. In addition all those who are HIV-positive, unemployed and have a CD4 count of less 
than 200cells/mm3 are entitled to a government disability grant of about R700 per month. 
This grant is meant to allow patients to have decent nutrition and be able to meet simple day 
to day needs like transport costs during their time of illness and therefore help them recover 
quickly. Patients are therefore expected to be diligent in taking their treatment. 
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 The South African ARV roll-out programme is using the following drugs: 
Nucleoside Reverse Transcriptase Inhibitors: Zidovudine (AZT), Lamuvidine (3TC), 
Stavudine (ZERIT), Didanosine (VIDEX), Non-Nucleoside Reverse Transcriptases 
(NNRTIs): Efavirenz (EFV), Nevirapine (NVP) and Protease Inhibitors (PIs): Kaletra. 
 
Description of the Study Location 
This study was carried out at two hospitals in the City of Johannesburg, Gauteng Province.  
Gauteng is the smallest of all South African provinces.11 The province is subdivided into 12 
administrative municipalities, the City of Johannesburg Metropolitan Municipality being one 
of them.11 The City of Johannesburg was sub-divided into 11 health and administrative 
regions, (region 1-11) but this is being changed into 7 regions as of November 2006, region 
(A- G) (See Map 1 page 6) 
 
Socio-demographic and economic status of the population  
The Gauteng province has an estimated population of about 8.8million.12 Gauteng is the 
economic habour of South Africa and is growing rapidly.11 The largest number of 
unemployed adults in Johannesburg is found in region D and G (Soweto, Orange farm).13 
These are areas of immense poverty, compounded by low education levels and there are 
large areas of informal settlements.14 A large proportion of Johannesburg residents live in 
Soweto. This is estimated to be about a third of the City of Johannesburg’s population.15 
Many parts in Soweto rank among the poorest in Johannesburg although individual suburbs 
in Soweto tend to have a mixture of wealthier and poorer residents.15  
It is estimated that 8.4% of Johannesburg residents aged 20 and over have received no 
schooling, 11.2% have some schooling, 34% have some high school education, 28% have 
finished high school and 12.6% have tertiary education.12 The education profile of the City of 
 4
 Johannesburg will be used as a reference against which those on HAART at the two sites 
are assessed. 
 
The ARV sites  
The two hospitals involved in this study were Chris Hani Baragwanaath Hospital (CHB) and 
Helen Joseph (HJ). CHB a public hospital is one of the 40 Gauteng provincial hospitals. It is 
located in Soweto in region D. CHB is the largest hospital in the world with about 3200 
beds.16 Nearly 2000 patients are seen at this hospital daily.16 It could be running one of the 
biggest ARV roll-out sites in the country. It caters not only for Soweto residents but for the 
residents in regions F, G, as well as people from other municipalities and provinces. HJ is 
also a provincial hospital but smaller than CHB located in region B. This is a 500 bedded 
hospital. 
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 Map 1: City of Johannesburg Metropolitan Municipality 17
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 1.2 Statement of the problem and justification for the study 
 
Despite the advent of effective combination of antiretroviral therapy (ART) for the treatment 
of HIV infection many doubt the feasibility of ART treatment programmes in resource-poor 
settings.18 The socio-demographic features of those who are HIV positive in the developed 
world are different from those who are HIV-positive in developing countries. The poor are 
the most affected by HIV in the developing world as it is a heterosexual epidemic in this 
context. The sex /gender distribution of the infection is also different for the two contexts. 
There are more infected females in the developing countries than in developed countries. 
Women in sub-Saharan Africa bear a disproportionate burden of the disease. Across sub-
Saharan Africa women are more likely to be infected than men and they are the ones more 
likely caring for the infected.2 In this region for every 10 men living with HIV there are about 
14 women who are infected with the virus.2  The age profile of those infected also differs by 
sex. It was reported that 15–49-year old adults are the most affected.19  Due to lack of 
knowledge and resources most patients in the third world present in the late stages of the 
disease, with very low CD4 counts, high viral loads and an array of opportunistic infections. 
“Those presenting for care with very low CD4 cell counts may make large demands on 
clinical resources, particularly over the first few months”.20  The availability of cheaper 
generic antiretroviral drugs complimented by the massive treatment thrust of the WHO 3 by 
5 initiative has brought a lot of hope for the infected and affected in Sub-Saharan Africa. The 
benefits of antiretroviral drugs are being appreciated in the region now despite other 
controversial theories and mistrust. 
 
This study is set to assess the impact of socio-demographic factors on response to HAART 
in the developing world at large public health facilities outside controlled research settings. 
This is in an endeavour to assess population effectiveness of the programme despite low 
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 socio-economic status of the population. Population effectiveness is an important public 
health measure of the impact of treatments.21 
 
The standard antiretroviral treatment prescribed for a treatment naïve patient, also known as 
Highly Active Antiretroviral Therapy (HAART), consists of a combination of at least three 
drugs; two NRTIs with an NNRTI or a protease inhibitor. These combinations are known to 
provide potent suppression of HIV-1 RNA in treatment naïve patients.22 
 
The hallmark of triple combination HAART has been profound suppression of viral load to 
undetectable levels (<400 copies/ml) with increases in CD4 cell count.1 Current therapeutic 
guidelines recommend achieving an undetectable viral load, preferably <50copies per/ml 
and at least less than 400copies/ml.23 However once this is achieved this does not 
guarantee sustainability, cases of viral load rebound to levels above undetectable levels are 
seen after initial viral suppression.23**
Positive responses to antiretroviral are expected to be increasing CD4 counts and lowered 
viral loads. In real practice this has not always been the case. Discordant virological and 
immunological responses have been observed.10**, 24 Immunological and virological failures 
have been observed to occur independently during HAART.10** To realize sustained full 
response and reduced resistance, adequate doses and strict adherence to therapy are 
important prerequisites. In the developed world there has been noticeable decrease in the 
AIDS morbidity and mortality due to access to drugs.  
 
 
 
** the original article quoted in journal 10 and 23 could not be traced. 
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 A lot of questions still remain unanswered regarding the effect of other factors peculiar to the 
region, such as socio-demographic characteristics, late presentation and opportunistic 
infections. These factors might have an impact on the sustainability of a therapeutic 
response to HAART which leads to the aim of this study.  
 
The aim of this study is to explore the relationship between a range of socio-demographic 
factors and response to HAART. The links between these are explored in the literature 
review. 
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 CHAPTER 2 LITERATURE REVIEW 
 
2.1. General 
Many studies and trials to confirm the effectiveness and responses to HAART Highly Active 
antiretroviral therapy were carried out in North America and Europe. The main HIV subtype 
in these areas is B as compared to type C in Africa. A few studies carried out in Africa do 
indicate good therapeutic response to HAART in the short-term. Responses to antiretroviral 
therapy in Africa are in line with those obtained in industrialized countries.25 A study by 
Cassol and others, reported that among TB and Kaposi Sarcoma patients in South Africa 
started on NRTI/NNRTI based HAART, 93.8% and 80% respectively had undetectable HIV-
1 levels at 90 days.26 In a study done in Uganda it was shown that although many HIV 
infected people treated with ARVs in Kampala had advanced HIV disease, the majority of 
these patients experienced viral suppression and clinical benefit.27
 
The treatment regimen, virus subtype and adherence are not the only factors influencing 
response to HAART. There are other factors peculiar to the African region that might 
influence individual response to treatment, such as socio-demographic characteristics, 
nutrition, opportunistic infections and availability of care.  
 
2.2. Effect of age on response to HAART 
It appears age, may be an important determinant of response to HAART. Studies were done 
in the developed countries to assess the effect of age on response to HAART. No literature 
on African studies looking at age as a factor could be found. In a study done in the United 
Kingdom to investigate factors influencing increases in CD4 cell count in HIV-positive, 
treatment naïve patients starting HAART, mean CD4 increases were evaluated at 3, 6, 12 
and 24 months. It was reported that age was not associated with increases in CD4 cell 
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 counts.28 In another study in Australia, age was found to determine the level of immune 
response to HAART.29 The study population was comprised of males only. Younger age was 
independently associated with greater increases in CD4 cell counts, and higher absolute 
CD4 cell counts at 48 months. The EuroSida Study carried out across Europe and Israel 
confirmed this phenomenon.30 In a study of children done in the UK and Ireland, (The 
Collaborative HIV Paediatric Study), better immunological response was seen in younger 
children.31 However there was poor virological response in the younger children. 
 
In the USA an increased number of older HIV positive patients are being seen in practice 
and this trend is likely to become pronounced as the HIV-infected population ages as a 
consequence of effective treatment.32 Old age and being treatment naïve were identified as 
a predictor of a sustained virological response during HAART 10**, whilst younger age was 
shown to be a predictor of virological failure.10
 
2.3. Effect of ethnicity/race on response 
There is very little literature available describing the role of ethnicity in the response to 
HAART. There is an assumption that disease progression is more rapid in Africans than in 
non African people. In a UK study by smith and others found an association between white 
ethnicity and greater increases in CD4 count.28 Sixty three percent (63%) of the study 
population in this UK study was of white ethnicity. In contrast in another study by Frater and 
others no differences were found in the initial response to HAART between European 
(White) and African (Black/Asian).33 However in Frater’s Study there was a difference in the 
sustainability of the virological response. There was evidence of increasing viral load after 9 
months of treatment in the African group. From the literature there is no definite evidence to 
confirm the effect of race on response to HAART. 
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 2.4. Effect of sex on response 
Sex might be a significant factor determining response to HAART. 
The cause for gender difference in response to HAART is thought to be multi-factorial.21 The 
female hormonal make up and their more likely poor socio-economic status can influence 
response to HAART.21 In a UK study by Smith and others there was no association between 
sex and response to treatment.28 In another study carried out at Royal Free Hospital in the 
United Kingdom, women achieved virological responses at a faster rate than men but other 
clinical outcomes were not assessed.34 A later study suggested a possible benefit in women 
compared with men.35 A study on a EuroSIDA cohort showed no gender difference in 
response to HAART.36 Most of these studies were done in countries where males constitute 
a higher proportion of the patients. Therefore from the literature sex might have an impact 
on response to HAART. Studies done in Africa including South Africa have shown a higher 
proportion of females on antiretroviral therapy than males.37, 38, 39, 40 There is no evidence in 
the literature to show if there is any difference in response between the two groups.  
 
2.5. Effect of baseline CD4 count on response 
There is contradictory information on the impact of baseline CD4 cell count and viral load on 
response to treatment. The extent of the pre-existing level of immunodeficiency was found 
to influence response to HAART. There was better immunological response in those who 
had the lowest baseline CD4 count.21, 31 Higher pre-HAART viral load and lower pre-HAART 
CD4 and CD8 cell counts were associated with greater increases in CD4 cell counts during 
the first 3 months of HAART.28 In contrast an Australian study reported that poor 
immunological responders who did not reach 500cells/ul at 48 months showed lower nadir 
CD4 count than good responders.29 Studies carried out in the Khayelitsha programme by 
Medicins San Frontiers and University of Cape town in South Africa, have shown that 
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 patients with CD4 counts <50cells/mm3 at baseline have a significantly lower probability of 
survival than those with levels above.41 The same was reported in Cote d’voire.42
Some studies have shown that patients with a higher pre-HAART CD4 count are at an 
increased risk of immunological failure.10
 
In conclusion there appears to be contradictory evidence from a range of studies on the 
association between HAART and socio-demographic factors. Further this has not been 
specifically explored for the Gauteng area of South Africa. These observations lead to the 
aim and objectives of this study. 
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 Chapter 3 Objectives 
 
3.1 Aim: 
¾ Ascertain the role of various socio-demographic factors on positive response to 
HAART in Gauteng, making use of two sites. 
3.2 Specific Objectives 
1. To describe the socio-demographic characteristics of the patients in the Gauteng 
public sector ARV roll-out programme at two sites.  
2. Describe the clinical outcomes within the first 12 months 
3. To establish the association between socio-demographic factors and response to 
HAART at each site 
4. To establish the association between baseline CD4 count, viral load and response to 
HAART.  
5. To identify groups prone to side effects. 
6. To describe the occurrence of opportunistic infections in patients on HAART in the 
Gauteng roll-out programme. 
7.  To compare response to HAART by treatment center.  
8. To use the findings to inform the Gauteng Department of Health ARV roll-out 
programme. 
Definitions 
Naïve: Any patient who was recruited into the government roll-out programme and was 
receiving antiretroviral therapy for the first time in their lifetime.  
Non-Naïve, not-naïve, treatment exposed: These are patients who had received some 
form of antiretroviral therapy before joining the government roll-out programme. This could 
have been PMTCT, mono therapy, dual therapy or HAART. 
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 CHAPTER 4 METHODOLOGY 
 
4.1. Study Design  
This is a retrospective cohort, exploratory, secondary data, record review study and a 
comparison between two sites.  
Routinely collected socio-demographic data and clinical data were used to establish the 
impact of socio-demographic factors on response to HAART. 
 
4.2. Study Population: 
These two ARV sites were chosen because of their ARV management experience and the 
need to select sites at the outset of this study where a significant number of patients were 
on treatment for over a year. The study population were adult patients aged 18 years and 
above, enrolled on the antiretroviral roll-out programme between April 2004 and August 
2004 at these two sites in the City of Johannesburg. 
 
According to the Gauteng Department of Health, CHB had 873 patients on treatment by 
August 2004 and HJ had 650 patients on the register. These two sites commenced the roll-
out programme at the official beginning date i.e. the 1st of April 2004. All the patients were 
receiving free antiretroviral therapy, laboratory testing and comprehensive HIV 
management. Both treatment naïve and not naïve patients were included in the study. 
 
All patients went through a process of initiation into the roll-out programme before 
commencing therapy. This involved counseling on ARVs, disclosure, having treatment 
supporter and treatment adherence. There is a follow up system for patients who default. 
This has helped in getting information on deaths that occur at home. The follow up system is 
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 hampered by those on treatment changing addresses and contact numbers without updating 
hospital records.  
4.3. Sample size and sampling 
Available data from adult patients enrolled between April 2004 and August 2004 and treated 
for a year at the two sites was reviewed. The government roll-out programme officially 
started on the 1st April 2004.  
The study sample therefore comprises the patients that were enrolled at the beginning of the 
programme. Data was collected from 494 patient files at CHB out of a list of about 687 
patients. The CHB pharmacy dispensing list was used to identify this sample. 
Data for 159 patients was extracted from the computerized Helen Joseph data sets. 
There could be several reasons why my figures do not tally with the Department of Health’s 
figures. The most important ones being:  
(i) The exclusion of those under the age of 18 years. 
(ii) Inability to locate files at CHB, especially for patients who use more than one 
name. 
(iii)  Duplicate files for patients. 
Despite not getting access to some records both data sets are considered to be 
representative of those on ARVs at these sites. 
 
4.4. Data Collection 
A. General  
CHB hospital has an informed consent process applicable to patients attending the HIV 
clinic, seeking permission for unlinked data use for research purposes. The informed 
consent form was in the files for most of the patients but often not signed. CHB does not 
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 have computerized data sets, therefore all the information was collected manually from 
patient files. I had access to 498 files at CHB .Some of the files had some of the information 
required for this study missing. As a result the total number analyzed at every stage of 
analysis is not constant. 
 
HJ as a multi-study centre and has consent forms for the different studies but there were no 
consent forms for the government roll-out program. Therefore unlinked computerized data 
was extracted from the HJ data sets for this study. The data set had 161 patients enrolled 
during this defined period. 
 
B. Data extracted from records and data sets 
1. Exposure Variables 
Age was calculated from the date of birth and roll-out date. Sex, race, marital status, 
education status, residential area, employment status were collected where available. HJ 
data sets did not have data on marital status and education status. Baseline CD4 count and 
Baseline viral load were collected as clinical exposure variables. 
Data Management: For the baseline CD4 and viral load results in the naïve patients, the 
latest result before the roll-out date/start date was collected as long as it was done in 2004. 
For the not naive patients the latest result before the roll-out date was collected as long as 
it was done in 2004, because for most of these patients, the result before initiation of 
treatment was not available. 
2. Outcome variables 
(i). Viral load and CD4 count 
Viral load and CD4 count at 3, 6 and 12 months time points were collected where available. 
Data Management:  For some patients the tests were not done at exactly the expected 
time point. Some were done a bit earlier some were done later. The results for the 3rd month 
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 were taken from the latest results available between 8-16 weeks, for the 6th month the latest 
results taken between 20- 28 weeks, for the 9th month the latest taken between 32-40 weeks 
and for the 12th month the latest taken between 44-52 weeks. Calculating these periods was 
based on the on the start date for the naïve and on the roll-out date for the not naïve.  
 
The start date was when the patient was started on ARVs. The roll-out date was when the 
patient joined the government roll-out programme, these dates are the same for the naïve 
patients and they differ for the not  naïve patients. 
The viral load was log 10 transformed for easy analysis.  
 
3. Measuring Response 
a) Immunological response 
Immunological response was calculated as changes in CD4 count from baseline to 3, 6, and 
12 months time points, by simply subtracting the baseline values from the 3 month, 6month 
and 12 month values. 
(i) The mean and median CD4 count increases were derived and used as response. 
(ii) Achieving a CD4 count of >=200 in was also considered as positive 
immunological response.  
b) Virological response. 
Positive response was assessed in two ways. 
1 Analysis for the undetectable viral load was considered at <=400 (2.6log 10) 
copies/ml as a cut off and  
2 The <=50 (1.7 log 10) copies /ml and <=500 (2.7log 10) copies\ml undetectable 
levels were also used in this analysis for comparison with other studies. 
At a certain period the NHLS used the 400copies/ml as undetectable levels and currently 
the <50 is being used. 
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4. Clinical information collected 
The naivety status of the patient was confirmed. Any AIDS defining conditions before and 
during treatment were recorded. Occurrence of TB before and during treatment was also of 
interest was also recorded. 
 
C. Challenges 
• Challenges included pulling out files from the file room, going through each and 
every one of the 498 files at CHB collecting the required data before capturing it into 
Epi info questionnaires. 
•  Interference with the busy clinic in order to complete data collection. 
•  Inability to enforce the signing of the informed consent, even if it was already 
attached to most of the notes. 
• There was a problem of incomplete records. At each level of analysis there is 
missing data not necessarily due to death or loss to follow up but due to data not 
being collected and the timing of laboratory tests (i.e. the test falling out of the time 
point range. This creates potential bias in assessing both exposure and outcome 
variables.  
• Manipulating the DATA sets from HJ to suit my analysis was not an easy task. 
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 4.5. Data Analysis 
As the aim of the study was to assess the association between the socio-demographic 
factors of those on HAART and treatment outcomes (virological response and 
immunological response) at two ARV roll-out sites the following data analysis plan was 
used:. 
1. Data for each site is considered separately and then a comparison is made between the 
two sites. 
2. The socio-demographic status and clinical outcomes for the patients on HAART are 
described first. The clinical outcomes are described for the combined (naïve and not 
naïve) and for the naïve separately. 
3. Thereafter the association between the socio-demographic variables and treatment 
outcomes are assessed  
 
9 Epi Info was used for data entry.  
9 Stata 9 was the main statistical package used for analysis. 
9 T tests were used for comparing means, Chi square and fishers exact were used to 
find frequencies and association between the categorical variables  
9 Logistic regression was used to find the effect of ordered or continuous exposure 
variables and binary outcome. 
9 Regression was used to find the association between the defined continuous 
exposure variables and the continuous outcome variables. 
9 In a multivariate model, to assess the effect of the exposure variables to the outcome 
variables Multivariate regression was used.  
9 Statistical significance was assessed at the 5% significance level, giving 95% 
confidence interval sufficient for an exploratory study of this nature. 
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 The results of each site are presented and discussed followed by a comparison between the 
two sites.  
 
4.6. Ethical Considerations 
An ethical application supported by letters of permission from the Gauteng Health 
Department was submitted to the University of Witwatersrand Ethics Committee for ethical 
approval. CHB had an informed consent allowing the Department of Health to use the 
routinely collected data without personal identifiers for surveillance and research purposes. 
There was very little evidence of the signed informed consent although there is one in place. 
See attached copy of the consent. HJ as multi-study centre has a number of informed 
consent forms but the one for government roll out had not yet been approved by the ethics 
committee. Therefore unlinked data was extracted from the HJ data sets for this study. 
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 CHAPTER 5 RESULTS  
 
5.1 Introduction 
The results will be presented following the order of the objectives. Firstly the results for CHB 
will be described, and then followed by the results for HJ. The final section of this chapter 
compares the two sites. The findings are then discussed in the following Chapter. 
 
5.2  Chris Hani Baragawanaath (CHB) 
The hospital is described in Chapter 1 and 4. 
5.2.1. Socio demographic factors 
The results on socio-demographic factors are summarized in Table 5.1, Graphs 5.1 and 5.2. 
 
A. Sex and Age 
Females constituted 60.9 % (n=298) of the patients. The mean age of the patients at CHB 
was 35.9 years. Females had a lower mean age than males, 34.5 and 38.1 years 
respectively (p=0.000). The detailed age analysis showed that the majority of men and 
women were in the age group 30-39 years although women predominated in the 20-29 age 
category and men in the 40-49 age groups. Overall, 6.1% of all the patients were more than 
50 years old. (See Table 5.1; Graphs 5.1 and 5.2)  
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 Table 5.1: Summary: socio-demographic factors (CHB) 
Sex  
Female (n=298) 61% 
Male (n=191) 39% 
  
Age (in years) (n=493) 
Mean (standard deviation) 34.9 (7.81) 
  
Education status  
No education (n=4) 1.0 % 
Grade 0-5 (n=35) 8.8% 
Grade 6-7 (n=44) 11.1% 
Grade 8-12 (n=296) 74.8% 
Higher education (n=17) 4.3% 
  
Employment (n=480) 
Employed/self employed 18.1% 
Unemployed on grant 51.9% 
Unemployed not on grant 30% 
  
Marital status  
Married  (n=68) 13.9% 
Single (n=376) 77.1% 
Divorced or seperated (n=22) 4.5% 
Widowed (n=22).4.5% 
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 Graph 5.1: Categorised Age (CHB)  
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Graph 5.2: Categorised Age by Sex (CHB) 
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B. Race 
The majority of the patients (97%) were African with a very small percentage of Coloreds 
and Indians.  
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 C. Education 
The education profile of the patients showed that over three quarters (79%) of the patients 
had achieved at least grade 8. The proportion of those on ARVs who had tertiary education 
was 4.3% and those with no schooling were 1%. (See Table 5.1) 
There were a higher proportion of females compared to males with at least grade 8 
(85%vs.67%) (p=0.000). 
 
D. Employment 
Of the 480 records analyzed, only 18.1% of the patients were employed/self-employed, 
51.9% were unemployed but accessing a disability grant and the other 30 % were neither 
employed nor received a grant. (See Table 5.1) 
The sex breakdown by employment showed that a very similar percentage of men and 
women were employed (17.9% of females were employed as compared to 18.7% males). 
When assessing those receiving grants, there were slightly more females on grants than 
males (55.2% and 46.7%) respectively (p=0.149).  
 
E. Marital status 
Three quarters (77.1 %) of the patients were single, 13.9% were married. The balance 
(divorced, separated and widowed) constituted the other 9% in equal proportions. A higher 
proportion of males were married (22%) when compared to females (9%) (p=0.001). 
 
F. Residential Area 
More than three quarters (77%) of the patients lived in Soweto; the location of Chris Hanoi 
Baragwanath, A further (8%) came from an adjacent region, Region G within the City of 
Johannesburg (to the south). In total, (9.6%) of the patients came from outside of the City of 
Johannesburg. Refer to Map 1 page 6. 
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 5.2.2 Clinical outcomes 
 
A. General 
More than half (67.1%) were treatment naïve and the remainder were not naive.  
 
Type of treatment 
There were three, three drug combinations available as first line treatment for the naïve 
patients. More than three quarters (89.1%) of the naïve patients were on D4T, 3TC, EFV, 
followed by (9.7%) on AZT, 3TC, EFV and the rest were on D4T,3TC,NVP. 
The not naïve who constituted a third of the sample had more than five combinations of 
treatment available which included DDI and Kaletra which are not in the first line for the 
naïve. More than a quarter (40%) were on AZT, 3TC, EFV, a quarter (25.7%) were on D4T, 
3TC, EFV, (18.8%) were on D4T, DDI, EFV and the rest were on other combinations. 
 
Treatment change and Side effects 
In the combined group more than (20%) had their treatment changed during the year. This 
proportion was high due to a sizeable number of the not naïve patients starting on a new 
regimen different from the one they had before the roll-out. Treatment was not changed for 
90% of the naïve patients. In the naïve the treatment change was mostly after 6 months of 
treatment, i.e. for about two thirds. The reasons for changing treatment in the naïve in order 
of proportions were; side effects (56.7%), treatment failure (33.3%), unknown, 6.7% and 
pregnancy (3.3%). In the combined group, the reasons for changing treatment in order of 
proportions, were, treatment failure (47.2%), side effects (24.5%), change to roll out drugs 
(21.7%), unknown (4.7%) and pregnancy (1.9%). Only( 6%) suffered side effects that 
warranted change of treatment. The proportions were similar in the combined group and 
naïve. 
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 General outcomes at 12 months 
Patients still on treatment 
At twelve months almost three quarters of the patients (74%) enrolled during the first four 
months of the roll-out programme were still on treatment.  
About (7%) had stopped treatment, transferred or their whereabouts was unknown. (See 
Graph 5.3) 
Graph 5.3: General outcomes  at 12 months(CHB) 
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Dead 
Nearly one fifth of the enrolled patients i.e. (19%) had died by the end of the first twelve 
months. Confirmation of deaths was obtained from hospital notes and reports from next of 
kin during follow up. The naïve had a higher proportion of deaths (22.8 %) than the not 
naïve (11%). 
Of all those who died, (61.7%) died in the first three months of the roll-out programme. 
Nearly three quarters (70.7%) of the dead had a baseline CD4 count <=50cells/mm3. More 
than half of the dead (53.2%) had TB prior to roll-out. Over three quarters (77.5%) of the 
dead came from region D. Among those who were still on treatment at 12 months, less than 
half (42%) had a baseline CD4count <=50 cells/mm3. 
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 Defaulters and Transfers 
Less than a tenth (6%) of the patients defaulted treatment in the first year of roll-out. 
A very small percentage (1%) was formally transferred to other roll-out centers. 
 
Opportunistic Infections: Occurrence of TB 
Tuberculosis 
Almost half (49.8%) of the patients had been treated for TB prior to roll-out programme. In 
the naïve 47% had TB before HAART was commenced. Less than a tenth (6.7%) of the 
naïve patients had TB after HAART was commenced. The proportions were similar in the 
combined group and the naïve. 
 
B. Immunological Response  
CD4 Count: As expected, the mean CD4 count for the combined group increased from 
85.1cells/mm3 at baseline to 261cells/mm3 at 12 months. However, this masks the variation 
between the naïve and the not naïve group in starting CD4 counts as well as treatment 
progression. 
The CD4 count of those who were treatment naive had a mean at baseline of 
58.9cells/mm3. At 12 months the mean CD4 count of those who were treatment naïve was 
245cells/mm3 as compared to 261cells/mm3 for the combined group. (See table 5.2) 
At the outset, three quarters of the treatment naïve, (77%) of the patients had a CD4 count 
of less than to 100cells/mm3, with (58%) starting with a CD4 count of less than or equal to 
50cells/mm3. At the outset, in the combined group (66.7%) had a CD4 count of less than 
100cells/mm3, with (48.3%) having a CD4 count of less than 50cells/mm3. Over the first 
three months after starting treatment, the treatment naïve responded quickly with an almost 
three fold (2.7 times) increase in mean CD4 counts during this initial period. In the naïve the 
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 median baseline CD4 count was higher in those >=50 years age group (81 cells/mm3 vs. 
57cells/mm3) as compared to those <50 years (p=0.062). 
Positive immunological response  
The mean/median CD4 count increase was higher in the naïve than in the combined group 
at all time points during the first 12 months. The median increase at 12months was 
177.1cells/mm3 for the naïve as compared with 169cells/mm3 for the combined group. (See 
Table 5.2 and Graph 5.4 below) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 29
 Table 5.2: Immunological and Virological outcomes(CHB) 
OUTCOME NAIVE NOT-NAIVE COMBINED 
pvalue 
Mean Baseline CD4 
count(cells/mm3)(sd) 
 
(n=330) 
58.9 (57.6) 
(n=148) 
143.6 (119.5) 
(n=478) 
85.1(90.7) 
 
0.000*** 
     
Mean CD4 count at 12 
months(sd) 
(n=200) 
245 (134.8) 
(n=89) 
297 (173.8) 
(n=289) 
261 (149.6) 
 
0.006****
     
Mean CD4 count 
increase at 12 
months(sd) 
(n=200) 
177.1 (123.5) 
(n=85) 
152.2 (145.6) 169 (130.7) 
 
0.141 
    
 
CD4 count >= 200 
cells/mm3 at 12 months 
(n=113) 
56.5% 
(n=53) 
66.3% 59.5% 0.117 
     
Baseline Viral load (log 
10copies/ml)(sd) 
(n=321) 
5.43 (0.6) 
(n=142) 
3.99 (1.36) 
(n=463) 
4.99 (1.12) 
 
0.000*** 
     
Viral load at 12 
months(log 10)(sd) 
(n=194) 
1.85 (0.92) 
(n=88) 
2.23 (1.17) 
(n=282) 
1.97 (1.01) 
 
0.003*** 
     
Viral load <=400(2.6 
log10) at 12 months 
(n=167) 
86.1% 
(n=60) 
68.2% 79.9% 
 
0.000*** 
     
Dead 
(n=76) 
22.8% 
(n=18) 
11% 19% 
 
0.004*** 
Died <=3months 
(n=47) 
61.8% 
(n=11) 
61.1% 61.7% 
 
0.702 
 
 
 
 
 
 
 
*** Statistically significant  
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 Graph 5.4: Immunological response( mean CD4 count increase) (CHB) 
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CD4 count>=200cells/mm3
(i) At 3 months 32 % of the naïve patients had a CD4 count of greater than 200 cells/mm3 
and. At 6 months 32.2% of the naïve patients had a CD4 count of >=200cells and as 
compared to 36.9% in the combined group. By 12 months 56.5% of the naïve patients had 
a CD4 count of >=200 cells and the proportion was 59.5% for the combined group. (See 
Graph 5.5) 
Graph 5.5: CD4 count>=200cells/mm3 (CHB) 
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 C. Virological Response. 
(See Table 5.2 and Graph 5.6). 
The viral load was transformed to the log 10 at data entry. 
The mean viral load for the combined group decreased from a baseline of 4.99 log 10 
copies/ml to 1.97 log 10 copies /ml at 12 months 
Positive Virological Response  
Viral load <= 400 copies/ml (CHB) 
(i) As from 3 months at least 85 % of the naïve patients had positive response i.e. viral load 
<=400copies/ml, 
(ii) In the combined group this was about 80% at 3 months dropping to less than 80% at 
12months. Similar proportions of positive virological response results were shown when only 
those with complete viral load results at all time points were analyzed. 
(iii) In the not naïve positive response was just above (75%) at 3 months and 6 months, 
falling to 68% at 12 months. 
The combined group had just about half (57.3%) of the patients <= 1.7 log10 (50copies) at 
12 months compared to the naïve who had nearly three quarters (73.2%) of the patients 
<=to 1.7 log 10 (50) copies/ml 
Graph 5.6:  Virological response viral load <= 400 copies/ml (CHB) 
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 5.2.3. Association between socio-demographic factors and response at 12 
months. (See tables 5.3 and 5.4) 
A range of socio-demographic factors described in section 5.2.1 were assessed for their 
statistical relationship to immunological and virological response. In univariate analysis most 
of these socio-demographic factors have no effect on immunological response. Age and 
marital status were found to have an effect on response. Race and residential area were not 
analyzed because of the small numbers in the in the subgroups.  
9 Age effect: There is a negative correlation between age and immunological 
response. There is reduced immunological response with increase in age (p=0.001). 
In categorized age, the <50years group have better immunological response than 
the >=50 years group (p=0.047). This association was found to be significant at 12 
months of treatment. At 12 months on HAART it was found that there is better 
virological response with increasing age. 
9 (ii) Marital Status effect: the widowed had reduced immunological response as 
compared to the (single, the divorced/separated and the married). 
 
 
 
 
 
 
 
 
 
 
***Stastically significant. 
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 Table 5.3: Regression of socio-demographic variables and increase in CD4 count at 12 months. (CHB) 
Variable Coefficient, Confidence, intervals ,pvalues  
 coefficient 95% Cl pvalue 
Sex: female ref   
Sex: male -11.9 -43.3 - 19.5 0.456 
    
age -3.49 -5.45 – (-1.53) 0.001*** 
    
Education: grade 7 and 
below ref   
Education grade  8 and 
above  21.44 -19.14 – 62.02 0.299 
    
Employed ref   
Unemployed on grant 24.6 -16.8 - 66 0.243 
Unemployed not on grant 30.1 -15.7 - 75.9 0.197 
    
Marital status: married ref   
Marital status: divorced 37 -38.57 - 112.5 0.336 
Marital status: single -26.4 -69.8 - 17 0.232 
Marital status: widowed -108 -183.7 - (-32.5) 0.05*** 
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 Table 5.4: Logistic regression of socio-demographic variables and viral load <=400 copies/ml at 12 
months. (CHB) 
 Odds ratio and Confidence intervals   
 OR 95% Cl pvalue 
Sex: male 1.4 .7 - 2.5 0.338 
    
Age 1.04 1 - 1.08 0.046*** 
   0.366 
Education: (Grade 8 –
tertiary) 0.62 0.257 – 1.486 0.282 
    
Unemployed on grant 0.8 0.4 - 1.8 0.611 
unemployed not on grant 1.4 0.5 - 3.5 0.496 
    
Marital status: single 2.7 0.8 - 9.25 0.106 
Marital status: divorced 1.2 0.25 - 5.54 0.828 
Marital status: widowed 0.72 0.19 - 2.72 0.627 
 
 
5.2.4 Association between Baseline CD4 Count, Baseline Viral Load and 
Response at 12 months (See Table 5.5)  
Table 5.5: Regression of Baseline CD4 count, Baseline viral load and response at 12 months (CHB) 
Baseline CD4, Baseline Viral load and increase in CD4 count at 12 month 
 Coefficient 95% CI pvalue 
Baseline CD4 count -0.17 -0.35 – (-0.001) 0.048*** 
    
Baseline viral load 14.9 1.2 - 28.5 0.033*** 
Baseline CD4, Baseline Viral load and viral load <=400 copies/ml at 12 
months 
 Coefficient 95% CI pvalue 
Baseline CD4 count 0.00003 -.0005 - 0.0005 0.916 
    
Baseline viral load 0.02 -.02 - 0.06 0.39 
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9 Baseline CD4 count effect: Baseline CD4 count has an effect on immunological 
response. Every unit increase in baseline CD4 count is associated with reduced 
immunological response. It has no effect on virological response. 
9 Baseline Viral Load Effect: It has an effect on immunological response. The higher 
the baseline viral load the higher the CD4 increase. It has no effect on virological 
response. 
 
Multi-variate analysis at 12 months  
Immunological response 
In a multivariate model using regression, adjusting for, age, age_50, marital status, baseline 
viral load, baseline CD4 count and sex at 12 months. Age was the only factor which had an 
effect on immunological response. 
Virological Response 
After adjusting for age, age_50 marital status, baseline viral load, baseline CD4 count and 
sex there was no difference in virological response between groups at 12 months.  
 
5.2.5. Groups prone to side effects 
There is no pattern in the occurrence of side effects. No particular group is particularly 
affected by side effects.  
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 5.3 Helen Joseph (HJ) 
Helen Joseph as a hospital is fully described in Chapter1 and 4. 
 
5.3.1. Socio demographic factors (See Table 5.6) 
Table 5 .6: Summary: Sex, age, employment, (HJ).  
  
Sex  
Female (n=96) 60.4% 
Male (n=63) 39.6% 
  
Age  n=158 
Mean (sd) 36.3 (8.2) 
  
Employment status  
employed/self employed (n=44) 36.1% 
unemployed on grant (n=7) 5.7% 
unemployed not on grant (n=71) 58% 
 
A. Sex and Age 
The majority of the patients were female (60.4%). The mean age in the sample was 36.3 
years. Females had a slightly higher mean than males 36.8 years and 35.7years (p=0.432) 
respectively. The median age was 35 years for the group and for both sexes.  
The peak age for both sexes was between 30 and 39 years. Less than a tenth of the 
patients were >=50 years. The female proportion was higher than the males in the 45 years 
and above age group. (See Graphs 5.7 and 5.8). 
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 Graph 5.7: Categorised Age (HJ) 
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Graph 5 8: Categorised Age by sex (HJ) 
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B. Employment Status 
More than a third (36.1%) was employed/self-employed. Just above half (58%) were 
unemployed and not on grant. A very small percentage of patients were on grant. 
Employment status by sex showed that a similar percentage of females and males were 
employed (35.5% vs. 37%). (See Table 5.6) 
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 C. Race 
The majority of the patients were African (95.4%). 
 
D. Place of Residence 
Just about a third (36.8%) of the patients came from region B, followed by about 17.6% and 
16.5% from region D and F respectively. Almost a similar proportion (14.9%) came from 
outside the City of Johannesburg. The remainder came from the other regions of 
Johannesburg and the province.  
 
5.3.2 Clinical Outcomes (HJ) 
 
A. General 
There was no information on PMTCT on the data set, therefore the not naïve were only 
those who were on any antiretroviral therapy before joining the roll-out programme. Very few 
patients had viral loads results recorded. None (0%) of the HJ patients have all their results 
recorded. 0% had all their viral load results recorded. only 4% had all their CD4 Counts 
available. The rest had one or two results available. More than three quarters of the patients 
(81.4%) were treatment naïve. 
 
Type of treatment 
More than three quarters (84%) of the naïve patients were on D4T, 3TC, EFV and about 
10% on NVP, 3TC, D4T. Almost half (44.8%) of the not naïve patients were on D4T, 3TC, 
EFV followed by 24.1% on a PI or DDI containing combination. There was more than one 
type of PI available for these patients. 
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 Opportunistic Infections: Occurrence of TB 
Less than a tenth (7.7%) of the patients had TB prior to roll-out. The proportions were similar 
in both the naïve and not naïve (7.89% vs. 7.4%). Less than one percent (0.71%) was 
treated for TB after roll-out and they were all naïve. 
 
General outcomes at 12 months 
Defaulters, transfers, dead, and patients still on treatment.  
The data set did not have enough information to describe this group. 
There were 3 confirmed deaths within the first year of treatment i.e. (1.9%) of the sample. 
Another (5%) had no other results after roll-out. There could be defaulters, transfers and 
other deaths in this group. 
 
B. Immunological Response 
CD4 count: The mean CD4 count for the combined group increased from 109.2 cells/mm3 
at baseline to 295.3 cells/mm3 at 12 months. The mean for the naïve was much lower than 
for the combined group 78.4 cells/mm3 at baseline to 268.2 cells/mm3at 12 months. 
Just above a third (39.6%) of the naïve patients had a baseline CD4 count <= 50 cells/mm3 
as compared to (33.3%) in the combined group. Two thirds (64.2%) of the naïve patients 
had a baseline CD4 count <=100 cells/mm3 as compared to (56.1%) in the combined 
group.  
The median baseline in the >=50year old group was higher than in the <50 years 82 
cells/mm3 vs.62 cells/mm3 (p=0.820). 
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 Positive immunological response 
This was measured as described for CHB. 
The mean CD4 count increase was higher in the naïve than in the combined group at all 
time points. The mean increase at 12 months for the naive was 188.8cell/mm3 vs. 
187.3cells/mm3 for the combined group. (See Table 5.7 and Graph 5.9). 
 
Table 5.7: Immunological response and Virological response (HJ) 
OUTCOME NAIVE NOT-NAIVE COMBINED 
 
 
pvalue 
Mean Baseline CD4 
count(cells/mm3)(sd) 
(n=106) 
78.4 (58.5) 
(n=24) 
232 (173.9) 
(n=) 
109.2 
 
0.000*** 
     
Mean CD4 count at 12 
months (sd) 
(n=52) 
268.2 (138) 
(n=11) 
389.5 (222) 
(n=63) 
295.3 (160.9) 
 
0.0218*** 
     
Mean CD4 count 
increase at 12 
months(sd) 
(n=43) 
188.8 (128.3) 
(n=11) 
171.7 (173,5) 
(n=55) 
181.7 (136.5) 
 
0.715 
     
CD4 count >=200 
cells/mm3 at 12 months 
(n=52) 
53.8% 
(n=11) 
81.8% 
(n=64) 
59.4% 
 
0.087 
     
Baseline Viral load (log 
10 copies/ml)(sd) 
(n=10) 
4.97(4.35) 
(n=12) 
4.23(4.77) 
(n=23) 
4.78(4.98) 
 
0.046 
     
Viral load at 12 
months(log 10)(sd) 
(n=42) 
3.60(4.35) 
(n=9) 
3.60(4.05) 
(n=52) 
3.60(4.32) 
 
0.992 
     
Viral load <=400(2.6 
log10) at 12 months 
(n=42) 
95.2% 
(n=9) 
88.9% 
(n=52) 
94.2% 
 
0.449 
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 (i) 53.8% of the naïve had a CD4 count >=200 copies/mm3 as compared to 59.4% for the 
combined group at 12 months (see Graph.5.10) 
 
Graph 5.9: Mean CD4 count increase (HJ) 
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Graph 5.10: CD4 count >=200cells/mm3 (HJ) 
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 C. Virological response 
(See Table 5.7 and Graph 5.11) 
Viral load results were not available for most of the patients and for some if they were 
available they were not in the defined time frame. There were very small numbers for 
analysis and this masks the differences or similarities between naïve and not naïve.  
The naïve started at a higher viral load mean than the not naïve (4.97 log 10 copies /ml 
vs.4.23 log 10copies /ml). At 12 months the two groups had similar viral load means 3.60 log 
10 copies /ml). A similar pattern is reflected in their medians.  
 
Positive virological Response  
Viral <= 2.6 log 10 (400) copies /ml, 
Positive response was assessed as for CHB 
As from 3months 95 % of the naïve patients had mean viral load below or equal to 400 
copies dropping to less than 90% at 6months and increasing to about 95% at 12 months, 
The naïve had a higher proportion at 12 months below this cut off level than the combined 
group. The naïve had more than 95% <= to 2.6 log10 (400) copies/ml compared to the 
combined group which had 90%.  
Using the 1.7 log10 (50) copies/ml, the naïve and the combined group had similar 
proportions of patients below or equal to 1.7 log10 (50) copies/ml at 12 months (40.5% vs. 
40.4%) 
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 Graph 5.11: Virological response Viral Load <=400 copies (HJ) 
0.0%
20.0%
40.0%
60.0%
80.0%
100.0%
120.0%
3mths 6mths 12mths
Time Point
Pr
op
or
tio
n 
(%
)
combined
naïve  
not naïve 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 44
 5.3.3. Association between socio-demographic factors and response at 12 
months 
The HJ socio-demographic factors described above were also assessed for their association 
with immunological and virological response.  
There was no association between all these factors and immunological response at 
12months. Association with virological response was not undertaken because of insufficient 
observations. (See Table 5.8) below 
 
Table 5.8: Regression of socio-demographics and increase in CD4 xount at 12 months (HJ) 
Variables coefficient and Confidence intervals  
 coefficient 95% Cl pvalue 
    
Sex: Female ref   
Sex: male 17.5 -57.5 - 92.4 0.641 
    
age 0.18 -3.9 - 4.1 0.953 
    
Employment: Employed ref   
Employment: Unemployed 
on grant -31.3 -210 - 147.5 0.726 
Employment: unemployed 
not on grant -52.5 -143.9 - 38.9 0.253 
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 5.3.4. Association between Baseline CD4 Count, Baseline Viral Load and Response at 
12months 
There were insufficient observations for assessing association between baseline viral load 
and virological response.  
Baseline CD4 count had an effect on immunological response. (See Table 5.9). 
9 Baseline CD4 count effect:  the effect was the same as for CHB. For every unit 
increase in baseline CD4count there is a decrease in response. This was only seen 
at 6 months.  
 
Table 5.9: Regression of Baseline CD4 count, Baseline viral load and response at 12 months (HJ) 
Baseline CD4, Baseline Viral load and Immunological response at 12 months 
 Coefficient 95% CI pvalue 
Baseline CD4 count -0.0060 -.4 - 0.34 0.974 
Baseline viral load -.0007 -.0030 - 0.0002 0.516 
 
Baseline CD4, Baseline Viral load and Virological response at 12 months 
 Coefficient 95% CI pvalue 
Baseline CD4 count 0.00003 -.0005 - 0.0005 0.916 
Baseline viral load 0.02 -.02 - 0.06 0.39 
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 5.4. Comparisons between CHB and HJ 
5.4.1 Socio-demographic factors 
The differences and the similarities between these two groups are masked by the small 
number of patients in the HJ sample. Some analyses are not possible for the HJ data 
especially where viral load is needed. 
 
A. Sex and Age 
The female to male proportion was the same for the two samples (60% vs. 40%).  The mean 
age for HJ was slightly higher than for CHB (36.3 vs.34.9 years) but statistically not 
significant (p= 0.579). The females in HJ had a higher mean age than the males as 
compared to CHB but this was not significant (p=0.433). 
B. Race 
The race proportions were similar for the two samples more than 95%of the patients were 
African. 
C. Employment  
HJ had a higher percentage of employed patients as compared to CHB, (36.1% vs.18.1%) 
(p=<0.001).At HJ only a small percentage (5.7%) was unemployed and on grant as 
compared to 51.9% at CHB. 
D. Residential Area 
HJ had about (15%) of its patients coming from outside the City of Johannesburg as 
compared to about (10%) for CHB. 
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 5.4.2. Clinical Outcomes 
 
A. CD4 count and immunological response 
The mean baseline was lower at CHB and this was significant (p=0.013). CHB had higher 
proportion of patients with baseline CD4 count <=50cells/mm3 (58.6 %) as compared to 
(39.6%) at HJ this was statistically significant (p=0.003). In the naïve the mean CD4 count 
increase was higher for HJ than CHB at all time points but this was not statistically 
significant p>0.05 at all time points.  
B. Viral Loads  
HJ had very few patients with viral load results which made it difficult to make meaningful 
comparisons between the two samples. 
At 12 months in the naïve patients, HJ, (95%) had viral load <=2.6 log10 (400) copies/ml as 
compared to (86%) at CHB. 
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 Chapter 6 Discussion 
 
The results of the study are explained and compared with other studies.  
 
There is no one way of monitoring and evaluating antiretroviral therapy. CD4 counts and 
viral load levels give an indication of response to therapy but at times they respond 
independently, once treatment has been commenced and thus they don’t always give the 
same story.  
 
6.1.1 General  
There was minimum variability between the two study sites. They were located in different 
regions. The other significant differences between the two samples were the proportions of 
those employed, naive and the mean baseline CD4 count. These were all lower in the CHB 
sample. The rest of the comparable socio-demographic factors and clinical factors were 
similar. These differences did not have an impact on the immunological response. The 
immunological response was similar in the two samples at all time points. HJ had very few 
viral load results and these might not adequately represent the sample. HJ data on side 
effects was not adequate and was omitted from the analysis.  
 
6.1.2 Type of treatment  
The majority of the patients were on WHO recommended regimens for the resource limited 
settings i.e. NNRTI-containing HAART regimen. In terms of the regimens the 2-NRTI 
backbone should consist of zidovudine or stavudine plus lamivudine. The primary NNRTI to 
be used includes efavirenz or nevirapine.43 All the naïve patients were on combinations of 
treatment containing the drugs mentioned above. More than 80% of the naïve were on D4T, 
3TC, EFV combination. 
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 6.2. Socio-demographic factors 
 
6.2.1. Age and Sex 
The mean age of patients on HAART at CHB and HJ were 34.9 years and 36.3 years 
respectively and this difference was not statistically significant (p=0.579), (the median for 
both samples was 35 years). The mean was similar to what was found in other African 
studies involving patients on HAART with the mean median from (34-38.8) years.37, 38, 39, 27 
The proportion of female patients on HAART was just above 60% in this study. This does 
not differ from other studies in South Africa and other African countries this ranged from (60-
70%).37, 38, 39, 40. This reflects the distribution of the HIV epidemic in Africa. Age and sex 
distribution of the patients in the study reflect the HIV prevalence distribution by age and sex 
obtained in a number of studies in South Africa.44, 45, 46 The >50 years age group constitute 
less than 10 % of the patients on roll-out.  
Although the females had higher mean CD4 increase at all time points after initiation of 
HAART this was not statistically significant. (p=0.456) for CHB and (p=0.642) for HJ at 12 
months. 
Sex had no effect on virological response (p=0.338) at 12 months at CHB. 
Age had an effect on immunological response. Age is negatively correlated to 
immunological response, as age increases immunological response is reduced, at CHB 
(p=0.001) at 12 months. This concurs with findings in a study done in the USA, among 
homosexual men but this was at 6 months.47 Other studies confirmed the same finding.48, 32
Age also has an impact on virological response as those who achieved undetectable viral 
load at 12 months (i.e.<=400copies/ml) were older than those with detectable viral loads 
(p=0.046) for CHB. Older age was associated with good virological response in other 
studies done in the developed countries, although different values were used as 
undetectable levels.49, 50, 32, 51 
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 6.2.2. Race 
Race comparisons were not possible because almost all patients were African above (95%) 
for both sites. The proportions that were still on therapy at 12 months i.e. (73 %) and the 
proportions that achieved undetectable viral loads at 6 months and 12 months i.e. (> 85%) 
for both sites are evident enough to show Africans do well on therapy. Their socio-economic 
status is likely to deter them from adhering to therapy thus resulting in reduced response. It 
is likely that findings would have been different if patients were sourcing their own 
antiretroviral drugs.  
 
6.2.3. Marital Status at CHB 
The majority of the patients were single (77%). Males had a higher proportion of the married 
than the females (21.8% vs.8.6%). There could be two explanations for this. 
9 Married women are not coming for HAART.  
9 The other explanation may be that the AIDS scenario in Gauteng might be different 
from the commonly accepted theory that the married women are more vulnerable.  
The widowed who constituted 4.5% of the patients showed lower immunological response 
as compared to the married (p=0.05) at 12 months. One explanation could be lack of a 
social support system compounded by ill health and increased responsibilities in the family 
structure when the spouse dies. 
 
6.2.4. Socio-economic status: Education, Employment and Residential area  
Interestingly the majority of the patients in the CHB sample are educated. More than three 
quarters (79.1%) had attained Grade 8 and above level of education. In some studies done 
to find the correlation between socio-economic status and HIV in Africans in South Africa 
there was no discernible trend.44 However HIV prevalence was significantly lower in those 
with tertiary as compared to those with no schooling or some schooling.44.This may explain 
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 the low proportion of patients with tertiary education in the study i.e. (4.3%). Another 
explanation for such a small proportion in the roll-out programme is that, this group can 
afford private health care thus they are being treated elsewhere.  
In contrast to popular belief that women are less educated, in this study there are more 
females in the high school and tertiary education groups (86% females as compared to 67% 
males) p=0.000. 
This raises a few questions. 
9 Are we not missing those with little or without schooling in this life saving 
intervention? This group is poorly represented in this sample? 
9  Is the message regarding access to ARV getting across to this group especially 
females? 
Education had no effect on both immunological and virological response to HAART, 
(p=0.299 and p=0.282) respectively at CHB.  
 
The majority of the patients were not employed i.e. (81 % for CBH and 63% for HJ.) 
Employment had no impact on both immunological and virological responses (p=0.197 and 
p=0.496) respectively. However employment had a significant impact on baseline CD4 
count. Baseline CD4 count was lower for those unemployed as compared to the employed 
(p=0.022). Those who were already receiving a grant had a slightly higher baseline CD4 
count than those who were not on grant. These differences disappear after HAART is 
commenced. 
 
The regions in which the two sites were located were socio-economically different. This is 
clearly reflected in the proportions of those employed (HJ 36% vs. CHB 18% p=<0.0001). 
The differences in baseline CD4 count between the two sites also reflect this socio-
economic inequality. A very low CD4 count is a sign of AIDS illness. AIDS current or 
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 previous was associated with current or recent poverty.52 The majority of patients on this 
study came from areas with a high number of informal settlements of Soweto and Orange 
Farm and according to the Nelson Mandela Study, persons in these settlements have by far 
the highest HIV prevalence (25.8%) compared with the national value of (16.9%).44
 
None of these socio-economic differences reflects on the immunological and virological 
responses to treatment at either site. This is a clear indication that the availability of 
continuous free comprehensive HIV care eradicates the baseline inequalities. The fact that 
all patients were receiving free comprehensive treatment, the real socio economic status 
which inhibits access to therapy and promotes non-adherence to treatment is eradicated or 
masked. In addition to free treatment, access to disability grants improves the socio-
economic status of the patients. These grants play an important role in mitigating the impact 
of HIV/AIDS.53 They reduce inequality and decrease the prevalence, depth and severity of 
poverty in affected households.53
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 6.3 Clinical outcomes 
 
6.3.1. General 
Clinical outcomes like the occurrence of death, opportunistic infections and malignancies 
are important indicators of disease progression and response to treatment. 
Mean CD4 increase and proportions of undetectable viral load are some of the important 
indicators needed for monitoring and evaluation of the programme.18  
 
6.3.2. CD4 count: Baseline and response 
It is physiologically known that relative to males, females have a higher CD4 count, whether 
HIV positive or negative. This has been found to have no functional significance.54 The 
female mean CD4 count at all time points after the start of HAART were higher than for the 
males in both combined and naïve analysis but this was statistically not significant. There 
was no gender difference in virological and immunological responses to therapy. This was 
similar to findings in a EuroSIDA study.36 
The naïve >=50 year age group had a baseline CD4 count higher than the <50 years age 
group (81cells/ mm3. vs. 57 cells/mm3). This concurs with earlier studies done in developed 
countries, older naïve patients i.e. those >= 50years tend to have a higher baseline median 
CD4 count than those less than 50 years although this age group is known to have reduced 
CD4 cell recovery.48,49
 
In the study (CHB data), a higher proportion of patients who died were in the group with a 
baseline CD4 count of <=50cells/mm3 as compared to those who had a baseline CD4 count 
>50cells/ mm3 (p=0.001). Studies done earlier showed that the naïve patients with a 
baseline CD4 count less than 50 cells/ mm3, were associated with an increased progression 
of clinical disease.55, 41
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 There was no association between those who had TB prior to roll-out and the CD4 count 
<=50 cells/mm3, neither was it associated with the occurrence of TB after commencing 
HAART. 
This study showed that both sites, just less than (60%) of the patients achieved a CD4 count 
of >=200 cells/mm3 at 12 months. This is lower than what another site in a South African 
rural setting revealed. This site in the Eastern Cape had (75%) of the patients achieving a 
CD4 count >=200cells/mm3.56 The cause for such a difference could be the differences in 
baseline CD4 counts between the two sites. 
Almost all the naïve patients in the CHB study have a baseline CD4 count of less than 
200cells/mm3. In this sample no patients with WHO stage III and IV disease who had a CD4 
count of greater than 200cells/mm3 were enrolled. A study done in Cape Town showed that 
individuals with stage III and IV disease regardless of their CD4 count had more AIDS 
events and deaths than those with stage I and II disease and a CD4 count less than 200 
cells/ul.57 Is this group not being missed in the programme? 
 
The median CD4 count increases were comparable to other studies.47, 43, 50, 27 In a study 
done in the USA the median increase inCD4 count of 160 cells/ml was recorded for the 
naïve patients at 12 months this is similar to our findings.43 Better short term and long term 
responses were seen in the naïve patients than the not naïve.47 This concurs with findings 
in this study, the naïve had better response than the not naïve at all time points. At 12 
months the mean CD4 count increase (CHB data) was 177.7cells/mm3 for the naïve and 
152.2cells/mm3 for the not naive. The short term (about 3 months) increase in the naïve 
(American European study) of 82cells/mm3 was comparable to findings in this study, CHB 
(93.3cells/mm3) and HJ (100cells/mm3) at three months.47
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 In this study, there was reduced immunological response with increase in baseline 
CD4count p=0.048.( See Table 5.5). In the USA the strongest responses in CD4 counts 
occurred among those who began with the lowest CD4counts.21
 
There is a steep improvement in the first phase up to week 12; the second phase beginning 
after week 12 has minimal increase in CD4 count which is then followed by a slightly steep 
rise in the third phase. The graph is therefore triphasic. (See Graph 6)The CD4 count rise in 
the naïve typically exhibits a biphasic pattern; the second phase begins after week 12.58  The 
difference between this study graph and the typical graph could be due to the much lower 
baseline CD4 count in this study. 
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6.3.2 Viral load response 
In this study more than (85%) of patients at both sites had undetectable viral load 
(<=400copies/ml) at 6 and 12 months. The proportion of patients with undetectable viral load 
at 6 months and 12 months is comparable and in other cases better than what has been 
found in other African countries.18, 43, 27 This is similar to what has been found in the 
developed world even under some research settings.59 In a collaborative analysis of 
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 European and North American patients on antiretroviral therapy, (83%) of the patients in 
2002-2003 had achieved an HIV-RNA (viral load) of 500 copies /ml by 6 months or less.59  In 
this study, virological response results compare favourably and even show better results 
than other South African ARV sites.60,  56  At 12 months the proportion of undetectable viral 
load (>85%) was still high as compared to results from Lusikisiki, which had (78%) 
undetectable rate in hospital settings.56  One study confirmed that availability of free 
medication had a significant impact on the mean proportion of subjects who had positive 
virological response.18 The provision of free antiretroviral therapy has been found to 
increase the proportions by between (29%-31%) at 6 months and 12 months.18
 
There might be variations between sites in South Africa, depending on the proportions of the 
naïve and not naïve patients. Treatment naive patients are more likely to reach 
undetectable levels (<400 copies/ml) than the not naïve.27, 47
The proportion was lower and progressively going down over the first year for the not naïve 
which raises the question of treatment failure. There are two main reasons to explain this 
failure, 
9 Is there emerging resistance already?  
9 Is it a question of adherence? 
 
Patients are expected to achieve undetectable viral load and maintain it after 6 months of 
HAART treatment.23 This appears to be true in the CHB data as there is an obvious increase 
from baseline to 3 months then to 6 months. From 6 months to 12 months this proportion 
appears to remain the same or slightly lower than at 6 months.  
Baseline viral load was found to predict virological success at 12 weeks and 24 weeks.61 In 
this study, baseline viral load had no effect on virological response at 12 months, (p=0.389). 
Unfortunately data was only available from one site, CHB. 
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 6.3.3. Opportunistic Infections: Occurrence of TB 
TB is the leading cause of mortality in the HIV infected and the TB epidemic is being driven 
by HIV.62 TB in a patient on ARVs poses a lot of challenges including adherence due to the 
increased pill burden.37 In two studies done in Africa (5%) of patients had to change 
treatment or withdraw from the study as a result of tuberculosis.43** In the CHB study more 
than half of the naïve patients who died had TB prior to roll-out although this was not 
statistically significant when compared to those who did not have TB (p=0.276). 
 
6.3.4. Side Effects  
The proportion of patients experiencing side effects at CHB was low (6%) but this could be 
an underestimation as those who experienced side effects which did not require change of 
treatment were not included in the data set. The commonly reported and confirmed side 
effects were peripheral neuropathy, lactic acidosis, anemia and lipodystrophy. Two studies 
in Malawi also recorded low levels of side effects.39, 40  One of the Malawian studies 
recorded adverse events as low a 3.7%.39 However in other African studies adverse events 
occurred in 14.3%-80.2%.43 Some of these were in research settings.  
 
6.3.5. Treatment change 
The major reason for changing treatment was treatment failure. There are two explanations 
for this.  
(i) Emerging drug resistance especially in the not naïve patients. 
(ii) Patients not adhering to treatment.  
Resistance to both NNRTIs and NRTIs has been documented in Africa.27, 43 These are the 
drugs used as first line treatment. 
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 6.3.6. Deaths and retention of patients 
In this study (61.7%) of deaths occurred in the first 3 months of treatment. A Malawian study 
in a rural setting showed that a similar proportion of deaths (61%) occurred in the first three 
months of treatment.39 In a Malawian study (12.6 %) died during the first year of HAART.39 
This is lower than what was found in this study which had (18.9%) deaths in the first 12 
months. At 12 months nearly three quarters (74 %) of the patients in this study (CHB) were 
still on treatment. This is similar to findings in other African countries, (79.8%)43 and (73%) in 
Malawi were still on treatment at 12 months. 
In this study HIV/AIDS was not the only cause of death in these patients. It is difficult to 
ascertain the cause of death in those who die at home. Road traffic accidents, chronic 
conditions e.g. diabetes, cardiopulmonary disorders contributed to these deaths. 
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 CHAPTER 7 CONCLUSION and RECOMMENDATIONS 
 
7.1 CONCLUSION 
1. The results from this study show that there is positive virological and immunological 
response to HAART in Gauteng ARV roll-out programme despite the low socio economic 
status of the majority of the patients. 
There is positive response on this large scale program which is comparable to what has 
been found in the developed world under research settings.  
2. The provision of free antiretroviral drugs and access to the disability grant has assisted in 
mitigating the effects of HIV/ AIDS on the socio-economically disadvantaged. 
3. Provision of HAART is taking the resource limited countries a step further in controlling 
the TB pandemic as the number of TB cases fall in the HAART treated patients. 
4. Age may affect immunological response. Age is the only socio-demographic factor which 
has a significant impact on immunological response to therapy. The elderly in this 
programme will need special attention  
5. The widowed are a vulnerable group they did not respond as well as the single, married 
or the divorced patients. There could be other psychosocial factors affecting the response of 
the older people and widows that need further research 
6. The group with no schooling is not represented in this sample, the question is whether the 
HIV/AIDS prevention and treatment message is accessible for this group. 
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 7.2 RECOMMENDATIONS 
1. There is a lot of clinical data for research purposes at CHB HIV Clinic This data cannot be 
accessed easily without going back to individual patient files.  
Investing in proper data capturing methods will make an important contribution to research 
for Monitoring and Evaluation purposes for the benefit of the Gauteng Health Department. 
HJ already has a computerised HIV data set, it is necessary to have comparable data sets 
for the whole province. This will make comparisons and combined analysis possible and 
easier.  
2. Further continuous research is needed as the ARV programme progresses to assess the 
sustainability of the outcomes confirmed by this study at 12months.  
3. Treatment failures have been observed, although still at low levels, further research is 
required to monitor closely adherence and the emergence of resistance.  
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